After mid-stage Parkinson's failure, UCB remains upbeat for next two shots on goal

UCB said Monday that its Novartis-partnered Parkinson's disease hopeful missed the primary and key secondary endpoints of the Phase IIa...
10 hours ago
from: FirstWord Pharma

Alpha-synuclein, Novartis, Parkinson's disease, UCB

More about this

- UCB’s Parkinson’s Drug Stalls As Curtain Comes Down On ORCHESTRA
Almost three years to the day, Novartis and UCB heralded a pact that could have been worth $1.5bn to the Brussels-based group for a...
from: Scrip

- UCB Parkinson’s candidate minzasolmin misses goal
Belgian drugmaker UCB today announced the ORCHESTRA proof-of-concept study of minzasolmin - an investigational, oral small molecule,...
from: The Pharma Letter

- UCB's orchestra hits dud note: Novartis-partnered Parkinson's asset fails phase 2
UCB's Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson's disease in a phase 2a trial. The oral...
from: FierceBiotech